Specialty Pharmacy

Lebrikizumab (Ebglyss; Eli and Lilly Company) is a monthly maintenance injection with proven efficacy in adults and children aged 12 to 18 years.

For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.

With the introduction of expensive drugs and associated challenges for hospital budgets, pharmacy leaders benefit from strategically managing financial, clinical, and regulatory factors for sustainable care delivery.

The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS).

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

Investigators obtained real-world evidence to evaluate the clinical outcomes of non-medical switching from the infliximab (Remicade; Janssen Immunology) to a biosimilar.

Guselkumab (Tremfya; Johnson & Johnson) is the first and only approved fully human and dual-acting monoclonal antibody blocking interleukin-23 and binding to CD64 receptors.

The company also submitted data from the ongoing phase 2 study, demonstrating the improvements of the investigational drug for symptoms of overall disease severity.

FCS is a severe, rare genetic disease in which patients have extremely high triglyceride levels, typically above 880 mg/dL.

Tocilizumab reduced relapses in 4 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

The FDA assigned a Prescription Drug User Fee Action date is January 31, 2025.

ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.

Myasthenia gravis is a chronic autoimmune disease that causes muscle weakness and fatigue, with 4 main treatment options available.

High-cost novel therapies challenge payers and patients, while biosimilars help balance affordability.

An examination of the 340B Drug Pricing Program's original intent, current challenges, and potential resolutions in today's complex health care landscape.

The application includes data from the Vivacity-MG3 study, demonstrating that individuals who received the drug had superior outcomes compared with the standard of care alone.

Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.

Pharmacists can provide extra resources for patients, including explanations of the therapy options for the patients, the course of therapy, and what patients can expect.

The use of surrogate markers was observed for breakthrough-designated indications that were approved through both traditional pathways and accelerated pathways.

Eight areas of improvement were developed as part of national initiative with stakeholder involvement.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

The guidance, if finalized, would revise considerations about switching studies for proposed interchangeable biosimilars.

In Finland, season of birth, notably autumn and winter, was associated with the development of asthma and allergic rhinitis.

This designation follows the drug's rare pediatric disease designation in July 2024.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Brandon Newman highlights the need for balanced regulation, transparency, and real-time data access to ensure fair competition and optimal outcomes for pharmacy benefit mangers.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

These pharmacies bring high-touch specialty pharmacies into local communities for patients with more complex needs.

Brandon Newman discusses the significant influence of the "big 3" pharmacy benefit managers and the key legislative and regulatory efforts around transparency.

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.